Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition of rosiglitazone and amiloride and application thereof

A composition and drug technology, applied in the field of medicine, can solve problems such as toxic side effects, heart enlargement, and increased mortality, and achieve the effects of simple preparation methods, reduced side effects, and good therapeutic effects

Inactive Publication Date: 2010-03-10
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Rosiglitazone is a PPAR-γ agonist of thiazolidinediones, which has been widely used in the treatment of type 2 diabetes, but long-term use of the drug has obvious toxic and side effects, which mainly manifests as water and sodium retention in the body, resulting in heart load increase and enlargement of the heart
A research report published on the website of "New England Journal of Medicine" (NEJM) in May 2007 clearly pointed out that the drug rosiglitazone (rosiglitazone), which is used to treat type 2 diabetes, has potential safety problems and can greatly increase Cardiac risk, resulting in increased mortality (Steven E, Wolski K, et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71)
[0004] So far there is no report about the pharmaceutical composition composed of rosiglitazone and amiloride for the treatment of polycystic kidney disease or type 2 diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition of rosiglitazone and amiloride and application thereof
  • Medicine composition of rosiglitazone and amiloride and application thereof
  • Medicine composition of rosiglitazone and amiloride and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] Now in conjunction with accompanying drawing, the present invention is described in detail.

[0017] Reagents and animal sources

[0018] Rosiglitazone: purchased from Changzhou Shanmei Drug Research and Development Center Co., Ltd.

[0019] Amiloride: purchased from Changzhou Shanmei Drug Research and Development Center Co., Ltd.

[0020] CMC-Na: purchased from China Pharmaceutical Group Shanghai Biochemical Reagent Company

[0021] Experimental animals: polycystic kidney disease model animal Han: SPRD rats, introduced by the Mayo Clinic in the United States.

[0022] Animal experiment: The therapeutic experiment of the pharmaceutical composition of the present invention on polycystic kidney disease model animals was taken out 30 male Han:SPRD young mice weaned 22 days after birth, with a body weight of 56-60 grams, and were randomly divided into 6 groups on average, respectively Blank control group, rosiglitazone group, amiloride group and low, middle and high dosa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, in particular to a medicine composition which consists of rosiglitazone and amiloride and can be used for treating polycystic kidneys or typeII diabetes. The rosiglitazone is widely applied to treating the type II diabetes, but has obvious side effect on the heart if application for a long time. The invention provides a medicine composition consisting of rosiglitazone and amiloride, which has obvious treatment effect on an Han:SPRD rat of a polycystic model animal without producing obvious side effects on the heart through animal experiments; the treatment for the mouse model suffered from the type II diabetes shows that: the medicine composition can obviously reduce the side effect of the rosiglitazone on the heart while treatingthe type II diabetes, thereby being used for preparing a medicament for treating the polycystic kidneys or type II diabetes. The invention provides a better prospect for the treatment of the polycystic kidneys or type II diabetes.

Description

technical field [0001] The invention relates to the technical field of medicine, and is a pharmaceutical composition composed of rosiglitazone and amiloride, which can be used for treating polycystic kidney disease or type 2 diabetes. Background technique [0002] Autosomal dominant polycystic kidney disease (ADPKD) is a common hereditary kidney disease. The pathological feature of ADPKD is mainly the formation of multiple large and small fluid cysts in both kidneys, which continue to grow, leading to damage to the structure and function of the kidneys, and eventually to renal failure. [0003] Rosiglitazone is a PPAR-γ agonist of thiazolidinediones, which has been widely used in the treatment of type 2 diabetes, but long-term use of the drug has obvious toxic and side effects, which mainly manifests as water and sodium retention in the body, resulting in heart load increase and enlargement of the heart. A research report published on the website of "New England Journal of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4965A61K31/4439A61P13/12A61P3/10
Inventor 梅长林王晓华胡惠民
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com